Erythropoetin beta twice weekly versus standard therapy in patients with gynaecological malignancies--a randomised Austrian AGO trial.

Birgit Volgger; Edgar Petru; Lukas Angleitner-Boubenizek; Monika Weigert; Alexander Reinthaller; Harald Lass; Anita Stempfl; Christian Gamper; Martina Deibl; Christian Marth

Erythropoetin beta twice weekly versus standard therapy in patients with gynaecological malignancies--a randomised Austrian AGO trial.

Birgit Volgger, Edgar Petru, Lukas Angleitner-Boubenizek, Monika Weigert, Alexander Reinthaller, Harald Lass, Anita Stempfl, Christian Gamper, Martina Deibl, Christian Marth

Department of Obstetrics and Gynecology

Research output: Contribution to journal › Original Article › peer-review

4 Citations (Web of Science)

Original language	English
Pages (from-to)	3977-3984
Journal	ANTICANCER RESEARCH
Volume	28
Issue number	6B
Publication status	Published - 2009

Keywords

QUALITY-OF-LIFE
PATIENTS RECEIVING CHEMOTHERAPY
ANEMIC CANCER-PATIENTS
PLACEBO-CONTROLLED TRIAL
WEEKLY EPOETIN-BETA
DOUBLE-BLIND
DARBEPOETIN-ALPHA
HEMOGLOBIN LEVELS
PHASE-III
SURVIVAL

Cite this

Volgger, B., Petru, E., Angleitner-Boubenizek, L., Weigert, M., Reinthaller, A., Lass, H., Stempfl, A., Gamper, C., Deibl, M., & Marth, C. (2009). Erythropoetin beta twice weekly versus standard therapy in patients with gynaecological malignancies--a randomised Austrian AGO trial. ANTICANCER RESEARCH , 28(6B), 3977-3984.

Volgger, Birgit ; Petru, Edgar ; Angleitner-Boubenizek, Lukas et al. / Erythropoetin beta twice weekly versus standard therapy in patients with gynaecological malignancies--a randomised Austrian AGO trial. In: ANTICANCER RESEARCH 2009 ; Vol. 28, No. 6B. pp. 3977-3984.

@article{24c7d0e77c044f04a6500756503783c2,

title = "Erythropoetin beta twice weekly versus standard therapy in patients with gynaecological malignancies--a randomised Austrian AGO trial.",

keywords = "QUALITY-OF-LIFE, PATIENTS RECEIVING CHEMOTHERAPY, ANEMIC CANCER-PATIENTS, PLACEBO-CONTROLLED TRIAL, WEEKLY EPOETIN-BETA, DOUBLE-BLIND, DARBEPOETIN-ALPHA, HEMOGLOBIN LEVELS, PHASE-III, SURVIVAL",

author = "Birgit Volgger and Edgar Petru and Lukas Angleitner-Boubenizek and Monika Weigert and Alexander Reinthaller and Harald Lass and Anita Stempfl and Christian Gamper and Martina Deibl and Christian Marth",

year = "2009",

language = "English",

volume = "28",

pages = "3977--3984",

journal = "ANTICANCER RESEARCH ",

issn = "0250-7005",

number = "6B",

}

Volgger, B, Petru, E, Angleitner-Boubenizek, L, Weigert, M, Reinthaller, A, Lass, H, Stempfl, A, Gamper, C, Deibl, M & Marth, C 2009, 'Erythropoetin beta twice weekly versus standard therapy in patients with gynaecological malignancies--a randomised Austrian AGO trial.', ANTICANCER RESEARCH , vol. 28, no. 6B, pp. 3977-3984.

Erythropoetin beta twice weekly versus standard therapy in patients with gynaecological malignancies--a randomised Austrian AGO trial. / Volgger, Birgit; Petru, Edgar; Angleitner-Boubenizek, Lukas et al.
In: ANTICANCER RESEARCH , Vol. 28, No. 6B, 2009, p. 3977-3984.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Erythropoetin beta twice weekly versus standard therapy in patients with gynaecological malignancies--a randomised Austrian AGO trial.

AU - Volgger, Birgit

AU - Petru, Edgar

AU - Angleitner-Boubenizek, Lukas

AU - Weigert, Monika

AU - Reinthaller, Alexander

AU - Lass, Harald

AU - Stempfl, Anita

AU - Gamper, Christian

AU - Deibl, Martina

AU - Marth, Christian

PY - 2009

Y1 - 2009

KW - QUALITY-OF-LIFE

KW - PATIENTS RECEIVING CHEMOTHERAPY

KW - ANEMIC CANCER-PATIENTS

KW - PLACEBO-CONTROLLED TRIAL

KW - WEEKLY EPOETIN-BETA

KW - DOUBLE-BLIND

KW - DARBEPOETIN-ALPHA

KW - HEMOGLOBIN LEVELS

KW - PHASE-III

KW - SURVIVAL

M3 - Original Article

C2 - 19192659

SN - 0250-7005

VL - 28

SP - 3977

EP - 3984

JO - ANTICANCER RESEARCH

JF - ANTICANCER RESEARCH

IS - 6B

ER -

Volgger B, Petru E, Angleitner-Boubenizek L, Weigert M, Reinthaller A, Lass H et al. Erythropoetin beta twice weekly versus standard therapy in patients with gynaecological malignancies--a randomised Austrian AGO trial. ANTICANCER RESEARCH . 2009;28(6B):3977-3984.